The risk of CRC can be reduced by using anti-inflammatory non-steroidals and cyclooxygenase-2 selective inhibitor celecoxib that demonstrate the central role of chronic inflammation in the cancer [49, 50]. The gene discussed is PTGS2; the disease is cancer.